Another mTOR inhibitor, temsirolimus, in combination with chemotherapeutic agent temozolomide, exhibited significant decrease in tumor growth and increased apoptotic death in melanoma cells that showed resistance to BRAF inhibitor vemurafenib [80]. This evidence concerns the gene MTOR and melanoma.